Patents by Inventor Eigen Peralta

Eigen Peralta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 12281329
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: April 22, 2025
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta
  • EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS
    Publication number: 20250032547
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: October 16, 2024
    Publication date: January 30, 2025
    Inventors: Emily CARRON, Eigen PERALTA, Bahram VALAMEHR, Hui-Yi CHU, Tom Tong LEE
  • Cells having solid tumor targeting backbone and use thereof
    Patent number: 12203098
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: January 21, 2025
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Tom Tong Lee, Martin Hosking, Eigen Peralta, Chia-Wei Chang
  • EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS
    Publication number: 20250000904
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: October 20, 2022
    Publication date: January 2, 2025
    Inventors: Emily CARRON, Eigen PERALTA, Bahram VALAMEHR, Hui-Yi CHU, Tom Tong LEE
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20240263135
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: February 14, 2024
    Publication date: August 8, 2024
    Inventors: Jonathan ROSEN, Betsy Denise REZNER, Ian HARDY, Eigen PERALTA
  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 12036241
    Abstract: Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 16, 2024
    Assignees: FATE THERAPEUTICS, INC., JUNO THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Eigen Peralta, Ian Hardy, Betsy D. Rezner, Christian Maine, Daniel Shoemaker, David Robbins, Lucas Thompson
  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 11932870
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: March 19, 2024
    Inventors: Jonathan Rosen, Betsy Denise Rezner, Ian Hardy, Eigen Peralta
  • ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS
    Publication number: 20240033355
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 1, 2024
    Inventors: Dan LU, Bahram VALAMEHR, Eigen PERALTA, Tom LEE, Alec WITTY
  • ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS
    Publication number: 20230390337
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 7, 2023
    Inventors: Bahram VALAMEHR, Eigen PERALTA, Chia-Wei CHANG
  • CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOF
    Publication number: 20230357716
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: June 30, 2023
    Publication date: November 9, 2023
    Inventors: Bahram VALAMEHR, Tom Tong LEE, Martin HOSKING, Eigen PERALTA, Chia-Wei CHANG
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20220401487
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: July 8, 2022
    Publication date: December 22, 2022
    Inventors: Jonathan ROSEN, Betsy REZNER, Bahram VALAMEHR, Ryan BJORDAHL, Eigen PERALTA, Ian HARDY
  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 11413309
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 16, 2022
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta, Ian Hardy
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20210393695
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: July 7, 2021
    Publication date: December 23, 2021
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta
  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 11096964
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 24, 2021
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20200181573
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: December 4, 2017
    Publication date: June 11, 2020
    Inventors: Jonathan Rosen, Betsy Denise Rezner, Ian Hardy, Eigen Peralta
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20200179451
    Abstract: Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.
    Type: Application
    Filed: July 19, 2018
    Publication date: June 11, 2020
    Inventors: Jonathan Rosen, Eigen Peralta, Ian Hardy, Betsy D. Rezner, Christian Maine, Daniel Shoemaker, David Robbins, Lucas Thompson
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20190282618
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: January 20, 2017
    Publication date: September 19, 2019
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta, Ian Hardy
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20190125795
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 2, 2019
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta
  • Oligomeric Compounds and Compositions for use in Modulation of Small Non-Coding RNAs
    Publication number: 20190062744
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: September 6, 2018
    Publication date: February 28, 2019
    Applicant: Regulus Therapeutics Inc.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
    Publication number: 20170268002
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: April 4, 2017
    Publication date: September 21, 2017
    Applicant: Regulus Therapeutics Inc.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta